Cardionate, capsules 250 mg 40 pcs

Pharmacodynamics

Synthetic analog of gamma-butyrobetaine, inhibits gamma-butyrobetaine hydroxylase, reduces carnitine synthesis and transport of long-chain fatty acids through cell membranes, prevents accumulation of activated forms of unoxidized fatty acids – acylcarnitine and acylcoenzyme A derivatives in cells.

As a result of a decrease in the concentration of carnitine increased synthesis of gamma-butyrobetaine, which has vasodilatory properties.

Under ischemic conditions meldonium restores the balance of oxygen delivery and consumption in cells, prevents the violation of adenosine triphosphate (ATP) transport: at the same time it activates glycolysis, which proceeds without additional oxygen consumption.

The mechanism of action determines the variety of pharmacological effects of meldonium: increased efficiency, reduction of symptoms of mental and physical stress, immune activation, cardioprotective effect.

In acute ischemic myocardial injury it slows the formation of necrotic zone and reduces the rehabilitation period.

In cases of cardiac insufficiency the drug increases myocardial contractility and tolerance to physical activity: reduces the frequency of angina attacks.

In acute and chronic ischemic disorders of cerebral circulation improves blood circulation in the focus of ischemia, redistributes blood in favor of the ischemic area.

A characteristic tonic effect on the central nervous system, elimination of functional disorders of the autonomic nervous system in withdrawal syndrome in patients with chronic alcoholism.

Pharmacokinetics

After oral administration the drug is quickly absorbed from the gastro-intestinal tract with the bioavailability of 78 %.

Maximum concentration in blood plasma is reached after 1-2 hours.

Metabolized in the body with the formation of two major metabolites, which are excreted by the kidneys.

Half-life period depends on the dose and is 3-6 hours.

Indications

For oral or intravenous administration: as part of complex therapy for coronary artery disease (angina pectoris, myocardial infarction), chronic heart failure, dyshormonal cardiomyopathy; as part of complex therapy of acute

and chronic cerebrovascular accidents (stroke and cerebrovascular insufficiency); decreased performance, physical overstrain (including in athletes), postoperative period to accelerate

rehabilitation; withdrawal syndrome in chronic alcoholism (in combination with specific therapy for alcoholism).

For parabulbar administration: acute circulatory disorders in the retina, hemophthalmos and retinal hemorrhages of various etiologies, thrombosis of the central retinal vein and its branches, retinopathy of various etiologies (including diabetic and hypertensive) – only for parabulbar administration.

Pharmacological effect

Pharmacodynamics

A synthetic analogue of gamma-butyrobetaine, inhibits gamma-butyrobetaine hydroxylase, reduces the synthesis of carnitine and the transport of long-chain fatty acids through cell membranes, prevents the accumulation in cells of activated forms of unoxidized fatty acids – derivatives of acylcarnitine and acyl coenzyme A.

As a result of a decrease in carnitine concentration, gamma-butyrobetaine, which has vasodilating properties, is intensively synthesized.

Under conditions of ischemia, meldonium restores the balance of oxygen delivery and consumption in cells, prevents disruption of adenosine triphosphate (ATP) transport: at the same time it activates glycolysis, which occurs without additional oxygen consumption.

The mechanism of action determines the variety of pharmacological effects of meldonium: increased performance, reduced symptoms of mental and physical stress, activation of the immune system, cardioprotective effect.

In case of acute ischemic damage to the myocardium, it slows down the formation of the necrotic zone and shortens the rehabilitation period.

In case of heart failure, it increases myocardial contractility, increases tolerance to physical activity: reduces the frequency of angina attacks.

In acute and chronic ischemic disorders of cerebral circulation, it improves blood circulation in the ischemic area, promotes the redistribution of blood in favor of the ischemic area.

Characterized by a tonic effect on the central nervous system, elimination of functional disorders of the autonomic nervous system during withdrawal syndrome in patients with chronic alcoholism.

Pharmacokinetics

After oral administration, it is quickly absorbed from the gastrointestinal tract, bioavailability is 78%.

The maximum concentration in blood plasma is achieved after 1-2 hours.

Metabolized in the body to form two main metabolites, which are excreted by the kidneys.

The half-life depends on the dose and is 3-6 hours.

Special instructions

When treating patients with chronic liver and kidney diseases, caution should be exercised, especially with long-term use of the drug.

There is insufficient data on use in children.

Impact on the ability to drive vehicles and machinery

There is no data on the adverse effects of the drug Cardionat® on the ability to drive vehicles and machines.

Active ingredient

Meldonium

Composition

The contents of the capsules are white or almost white crystalline powder with a slight odor;

The powder is hygroscopic, clumping is allowed.

1 caps. contains:

Meldonium dihydrate 250 mg

Excipients:

Potato starch – 13.3 mg,

Colloidal silicon dioxide (aerosil) – 5.7 mg,

Calcium stearate – 2.7 mg.

Composition of the capsule shell:

Gelatin,

Titanium dioxide

Pregnancy

During pregnancy and lactation (breastfeeding), the use of the drug is contraindicated.

Contraindications

Hypersensitivity to the main and/or auxiliary components of the drug; increased intracranial pressure (in case of impaired venous outflow and intracranial tumors); pregnancy; breastfeeding period; age under 18 years (efficacy and safety have not been established).

With caution

Chronic liver and/or kidney diseases (due to insufficient data).

Side Effects

From the cardiovascular system: tachycardia, decreased or increased blood pressure.

From the gastrointestinal tract: dyspeptic symptoms.

From the central nervous system: excitement.

Allergic reactions: redness and itching of the skin, rash, swelling.

Other: eosinophilia, general weakness.

Interaction

Can be combined with antianginal drugs, anticoagulants, antiplatelet agents. antiarrhythmic drugs and agents, etc. diure gikam i. bronchodilators.

Enhances the effect of coronary dilatants, some antihypertensive drugs, cardiac glycosides.

When used together with nitroglycerin, nifedipine, alpha-blockers. other antihypertensive drugs and peripheral vasodilators should be used with caution due to the possible development of moderate tachycardia and arterial hypotension.

Overdose

Symptoms: decreased blood pressure, accompanied by headache, tachycardia, dizziness, and general weakness.

Treatment is symptomatic.

Storage conditions

In a dry place at a temperature not exceeding 25°C.

Keep out of the reach of children.

Shelf life

3 years

Manufacturer

Nizhpharm JSC, Russia